Skip to content
Science and Education

    • Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer

    The Illumina Genomics Podcast

    Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer

    Nov 11, 2022 | Episode 76 | 6 mins

    Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and BRCA status in ovarian cancer patients. She presents the case of a patient who benefited from CGP testing for these biomarkers and shares the recent findings of the PAOLA-1 trial.

    Audio Player
    00:00
    00:00
    00:00
    Download or subscribe to our recurring podcasts.
    Apple Podcasts Google Podcasts Spotify RSS
    For Research Use Only

    Not for use in diagnostic procedures (except as specifically noted).

    Innovative technologies

    At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

    All trademarks are the property of Illumina, Inc. or their respective owners.
    For specific trademark information, see www.illumina.com/company/legal.html.

    © 2025 Illumina, Inc. All rights reserved.